Open Scanner

Specify a stock or a cryptocurrency in the search bar to get a summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Catalyst Pharmaceuticals Inc

CPRX
Current price
16.57 USD +0.58 USD (+3.63%)
Last closed 15.87 USD
Sector Healthcare
Industry Biotechnology
Exchange NASDAQ
Capitalization 1 874 484 992 USD
Yield for 12 month +43.46 %
1Y
3Y
5Y
10Y
15Y
CPRX
21.11.2021 - 28.11.2021

Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis and spinal muscular atrophy type. It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. The company was founded in 2002 and is based in Coral Gables, Florida. Address: 355 Alhambra Circle, Coral Gables, FL, United States, 33134

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
AAPL AAPL Apple
MSFT MSFT Microsoft

Analytics

WallStreet Target Price

27.29 USD

P/E ratio

28.3393

Dividend Yield

Current Year

+398 204 000 USD

Last Year

+214 203 000 USD

Current Quarter

+98 509 000 USD

Last Quarter

+110 568 000 USD

Current Year

+313 672 000 USD

Last Year

+179 810 000 USD

Current Quarter

+85 989 000 USD

Last Quarter

+85 700 000 USD

Key Figures CPRX

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
EBITDA 114 040 000 USD
Operating Margin TTM 27.54 %
PE Ratio 28.3393
Return On Assets TTM 9.29 %
PEG Ratio
Return On Equity TTM 14.55 %
Wall Street Target Price 27.29 USD
Revenue TTM 411 347 008 USD
Book Value 4.76 USD
Revenue Per Share TTM
Dividend Share
Quarterly Revenue Growth YOY 15.4 %
Dividend Yield
Gross Profit TTM 160 021 000 USD
Earnings per share 0.56 USD
Diluted Eps TTM 0.56 USD
Most Recent Quarter I 2024
Quarterly Earnings Growth YOY -26.9 %
Profit Margin 15.83 %

Dividend Analytics CPRX

Dividend growth over 5 years

Continuous growth

Payout Ratio 5 years average

Dividend History CPRX

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
Ex Dividend Date
Forward Annual Dividend Yield
Last Split Factor
Payout Ratio
Last Split Date
Dividend Date

Stock Valuation CPRX

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE 28.3393
Forward PE 10.352
Enterprise Value Revenue 4.1739
Price Sales TTM 4.5106
Enterprise Value EBITDA 13.8859
Price Book MRQ 4.6306

Financials CPRX

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Technical indicators CPRX

For 52 weeks

11.09 USD 17.5 USD
50 Day MA 15.68 USD
Shares Short Prior Month 7 710 507
200 Day MA 14.42 USD
Short Ratio 5.99
Shares Short 7 994 653
Short Percent 8.12 %

Dynamics of changes in the value of assets

Stocks


MSFT

MSFT

430.32 USD Microsoft Corporation +0.69 (+0.16%)
Detailed analytics

ETF funds


S

SX7EEX

14.75 EUR iShares EURO STOXX Banks 30-15 UCITS ETF (DE) 0 (0%)
Detailed analytics

Metals


Gold

2357.98 USD Gold +6.23 (+0.27%)
Detailed analytics